Cumberland Historical Income Statement

CPIX Stock

USD 4.41 0.28 6.78%

Historical analysis of Cumberland Pharmaceuticals income statement accounts such as Interest Expense of 635.8 K, Selling General Administrative of 9.1 M or Selling And Marketing Expenses of 17.5 M can show how well Cumberland Pharmaceuticals performed in making a profits. Evaluating Cumberland Pharmaceuticals income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Cumberland Pharmaceuticals's future profits or losses.

Cash Flow Balance Sheet Income Statement

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Cumberland Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Cumberland Pharmaceuticals is a good buy for the upcoming year.

Net Income Gross Profit

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cumberland Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

For more information on how to buy Cumberland Stock please use our How to Invest in Cumberland Pharmaceuticals guide.

About Cumberland Income Statement Analysis

Cumberland Pharmaceuticals Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Cumberland Pharmaceuticals shareholders. The income statement also shows Cumberland investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Cumberland Pharmaceuticals Income Statement Chart

At this time, Cumberland Pharmaceuticals' Depreciation And Amortization is fairly stable compared to the past year. Interest Expense is likely to rise to about 635.8 K in 2025, whereas Selling General Administrative is likely to drop slightly above 9.1 M in 2025.

Selling General Administrative Selling And Marketing Expenses Total Revenue Gross Profit

Total Revenue

Total revenue comprises all receipts Cumberland Pharmaceuticals generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Gross Profit

Gross profit is a required income statement account that reflects total revenue of Cumberland Pharmaceuticals minus its cost of goods sold. It is profit before Cumberland Pharmaceuticals operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.

Most accounts from Cumberland Pharmaceuticals' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Cumberland Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cumberland Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

For more information on how to buy Cumberland Stock please use our How to Invest in Cumberland Pharmaceuticals guide.At this time, Cumberland Pharmaceuticals' Depreciation And Amortization is fairly stable compared to the past year. Interest Expense is likely to rise to about 635.8 K in 2025, whereas Selling General Administrative is likely to drop slightly above 9.1 M in 2025.

	2022	2023	2024	2025 (projected)
Interest Expense	586.0K	667.9K	605.5K	635.8K
Depreciation And Amortization	5.3M	5.8M	6.0M	6.3M

Interest Expense Depreciation And Amortization

Cumberland Pharmaceuticals income statement Correlations

	Depreciation And Amortization	Interest Expense	Selling General Administrative	Selling And Marketing Expenses	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Research Development	Ebitda	Cost Of Revenue	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Net Income From Continuing Ops	Non Operating Income Net Other	Minority Interest	Tax Provision	Interest Income	Net Interest Income	Discontinued Operations	Reconciled Depreciation	Extraordinary Items
Depreciation And Amortization		0.77	0.62	0.22	0.23	0.09	0.64	-0.74	-0.81	0.54	-0.66	0.66	0.61	-0.75	0.06	-0.77	-0.29	-0.75	-0.55	0.43	-0.3	0.12	-0.76	-0.76	0.9	-0.53
Interest Expense	0.77		0.45	0.29	0.32	0.28	0.49	-0.34	-0.51	0.41	-0.36	0.3	0.52	-0.39	-0.32	-0.41	-0.14	-0.37	-0.53	0.41	-0.32	0.15	-0.82	-0.74	0.75	-0.58
Selling General Administrative	0.62	0.45		0.76	0.75	0.62	0.96	-0.39	-0.4	0.79	-0.27	0.84	0.95	-0.4	0.08	-0.53	0.19	-0.64	-0.07	0.17	-0.03	0.3	-0.31	-0.39	0.48	-0.12
Selling And Marketing Expenses	0.22	0.29	0.76		0.93	0.9	0.81	0.1	0.05	0.56	0.15	0.52	0.85	0.08	-0.03	-0.14	0.68	-0.28	0.26	-0.03	0.3	0.4	0.03	-0.1	0.04	-0.1
Total Revenue	0.23	0.32	0.75	0.93		0.98	0.79	0.23	0.18	0.58	0.32	0.56	0.81	0.22	-0.01	0.03	0.66	-0.13	0.07	0.06	0.09	0.12	-0.11	-0.14	0.12	-0.08
Gross Profit	0.09	0.28	0.62	0.9	0.98		0.66	0.41	0.32	0.45	0.45	0.36	0.71	0.39	-0.1	0.2	0.73	0.05	0.13	-0.01	0.11	0.12	-0.03	-0.05	-0.01	-0.1
Other Operating Expenses	0.64	0.49	0.96	0.81	0.79	0.66		-0.39	-0.37	0.84	-0.22	0.87	0.99	-0.4	0.12	-0.55	0.26	-0.63	-0.04	0.28	0.01	0.32	-0.33	-0.41	0.48	-0.08
Operating Income	-0.74	-0.34	-0.39	0.1	0.23	0.41	-0.39		0.94	-0.46	0.92	-0.55	-0.33	0.99	-0.2	0.95	0.6	0.87	0.2	-0.27	0.15	-0.3	0.36	0.45	-0.63	0.23
Ebit	-0.81	-0.51	-0.4	0.05	0.18	0.32	-0.37	0.94		-0.4	0.97	-0.47	-0.33	0.95	-0.05	0.92	0.57	0.86	0.28	-0.16	0.18	-0.35	0.44	0.53	-0.73	0.51
Research Development	0.54	0.41	0.79	0.56	0.58	0.45	0.84	-0.46	-0.4		-0.3	0.76	0.82	-0.47	0.13	-0.53	-0.06	-0.53	0.07	0.33	-0.28	0.27	-0.27	-0.3	0.47	-0.02
Ebitda	-0.66	-0.36	-0.27	0.15	0.32	0.45	-0.22	0.92	0.97	-0.3		-0.34	-0.18	0.93	-0.03	0.87	0.62	0.81	0.14	-0.04	0.12	-0.4	0.27	0.38	-0.59	0.47
Cost Of Revenue	0.66	0.3	0.84	0.52	0.56	0.36	0.87	-0.55	-0.47	0.76	-0.34		0.79	-0.54	0.32	-0.65	0.06	-0.76	-0.17	0.32	-0.04	0.07	-0.34	-0.38	0.56	0.0
Total Operating Expenses	0.61	0.52	0.95	0.85	0.81	0.71	0.99	-0.33	-0.33	0.82	-0.18	0.79		-0.34	0.06	-0.5	0.3	-0.57	-0.01	0.25	0.02	0.37	-0.32	-0.4	0.44	-0.1
Income Before Tax	-0.75	-0.39	-0.4	0.08	0.22	0.39	-0.4	0.99	0.95	-0.47	0.93	-0.54	-0.34		-0.11	0.96	0.6	0.87	0.2	-0.24	0.15	-0.33	0.39	0.44	-0.64	0.25
Total Other Income Expense Net	0.06	-0.32	0.08	-0.03	-0.01	-0.1	0.12	-0.2	-0.05	0.13	-0.03	0.32	0.06	-0.11		-0.11	-0.05	-0.19	-0.04	0.51	-0.03	-0.22	0.11	-0.3	0.08	0.16
Net Income	-0.77	-0.41	-0.53	-0.14	0.03	0.2	-0.55	0.95	0.92	-0.53	0.87	-0.65	-0.5	0.96	-0.11		0.35	0.93	0.16	-0.21	-0.04	-0.39	0.36	0.43	-0.64	0.25
Income Tax Expense	-0.29	-0.14	0.19	0.68	0.66	0.73	0.26	0.6	0.57	-0.06	0.62	0.06	0.3	0.6	-0.05	0.35		0.25	0.24	-0.19	0.62	0.01	0.28	0.25	-0.34	0.15
Net Income From Continuing Ops	-0.75	-0.37	-0.64	-0.28	-0.13	0.05	-0.63	0.87	0.86	-0.53	0.81	-0.76	-0.57	0.87	-0.19	0.93	0.25		0.13	-0.11	-0.1	-0.37	0.31	0.43	-0.61	0.31
Non Operating Income Net Other	-0.55	-0.53	-0.07	0.26	0.07	0.13	-0.04	0.2	0.28	0.07	0.14	-0.17	-0.01	0.2	-0.04	0.16	0.24	0.13		-0.53	0.26	0.65	0.84	0.64	-0.64	0.33
Minority Interest	0.43	0.41	0.17	-0.03	0.06	-0.01	0.28	-0.27	-0.16	0.33	-0.04	0.32	0.25	-0.24	0.51	-0.21	-0.19	-0.11	-0.53		-0.28	-0.34	-0.63	-0.74	0.49	0.08
Tax Provision	-0.3	-0.32	-0.03	0.3	0.09	0.11	0.01	0.15	0.18	-0.28	0.12	-0.04	0.02	0.15	-0.03	-0.04	0.62	-0.1	0.26	-0.28		0.11	0.36	0.29	-0.39	0.17
Interest Income	0.12	0.15	0.3	0.4	0.12	0.12	0.32	-0.3	-0.35	0.27	-0.4	0.07	0.37	-0.33	-0.22	-0.39	0.01	-0.37	0.65	-0.34	0.11		0.33	0.05	-0.03	-0.11
Net Interest Income	-0.76	-0.82	-0.31	0.03	-0.11	-0.03	-0.33	0.36	0.44	-0.27	0.27	-0.34	-0.32	0.39	0.11	0.36	0.28	0.31	0.84	-0.63	0.36	0.33		0.8	-0.81	0.37
Discontinued Operations	-0.76	-0.74	-0.39	-0.1	-0.14	-0.05	-0.41	0.45	0.53	-0.3	0.38	-0.38	-0.4	0.44	-0.3	0.43	0.25	0.43	0.64	-0.74	0.29	0.05	0.8		-0.8	0.42
Reconciled Depreciation	0.9	0.75	0.48	0.04	0.12	-0.01	0.48	-0.63	-0.73	0.47	-0.59	0.56	0.44	-0.64	0.08	-0.64	-0.34	-0.61	-0.64	0.49	-0.39	-0.03	-0.81	-0.8		-0.49
Extraordinary Items	-0.53	-0.58	-0.12	-0.1	-0.08	-0.1	-0.08	0.23	0.51	-0.02	0.47	0.0	-0.1	0.25	0.16	0.25	0.15	0.31	0.33	0.08	0.17	-0.11	0.37	0.42	-0.49

Click cells to compare fundamentals

Cumberland Pharmaceuticals Account Relationship Matchups

Cumberland Pharmaceuticals income statement Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Depreciation And Amortization	4.7M	4.6M	5.3M	5.8M	6.0M	6.3M
Interest Expense	263.6K	98.0K	586.0K	667.9K	605.5K	635.8K
Selling General Administrative	10.2M	9.8M	10.2M	10.7M	11.1M	9.1M
Selling And Marketing Expenses	14.8M	15.0M	16.7M	18.5M	17.0M	17.5M
Total Revenue	37.4M	36.0M	42.0M	39.6M	37.9M	39.9M
Gross Profit	28.8M	27.2M	32.9M	33.5M	31.3M	33.9M
Other Operating Expenses	43.8M	43.7M	47.7M	49.1M	44.3M	40.4M
Operating Income	(6.4M)	(7.7M)	(5.7M)	(6.2M)	(6.4M)	(6.1M)
Ebit	(6.3M)	(5.5M)	(5.0M)	(5.6M)	(12.5M)	(11.9M)
Research Development	5.8M	5.7M	6.7M	5.8M	4.8M	5.2M
Ebitda	(1.6M)	(857.8K)	332.9K	153.3K	(6.4M)	(6.1M)
Cost Of Revenue	8.7M	8.8M	9.1M	6.1M	6.6M	6.0M
Total Operating Expenses	35.2M	34.9M	38.6M	43.0M	37.7M	34.4M
Income Before Tax	(6.6M)	(5.6M)	(5.6M)	(6.3M)	(6.5M)	(6.1M)
Total Other Income Expense Net	(188.3K)	2.1M	123.7K	(74.2K)	(34.0K)	(32.3K)
Net Income	(6.6M)	(5.6M)	(5.7M)	(6.3M)	(6.5M)	(6.2M)
Income Tax Expense	55.9K	34.9K	68.9K	45.8K	(22.7K)	(21.5K)
Net Income Applicable To Common Shares	(3.5M)	(3.3M)	(3.5M)	(5.6M)	(5.0M)	(4.8M)
Net Income From Continuing Ops	(6.6M)	(5.6M)	(5.7M)	(2.5M)	(6.4M)	(6.1M)
Minority Interest	(79.5K)	95.2K	79.8K	62.9K	(36.1K)	(37.9K)
Tax Provision	55.9K	34.9K	68.9K	69.0K	(22.7K)	(21.5K)
Interest Income	75.3K	26.1K	98.4K	251.6K	334.4K	178.6K
Net Interest Income	(188.3K)	(72.0K)	(487.6K)	(417.0K)	(271.1K)	(257.5K)
Reconciled Depreciation	4.7M	4.6M	5.3M	4.2M	6.0M	4.8M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

Additional Tools for Cumberland Stock Analysis

When running Cumberland Pharmaceuticals' price analysis, check to measure Cumberland Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cumberland Pharmaceuticals is operating at the current time. Most of Cumberland Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Cumberland Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cumberland Pharmaceuticals' price. Additionally, you may evaluate how the addition of Cumberland Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Cumberland Historical Income Statement

About Cumberland Income Statement Analysis

Cumberland Pharmaceuticals Income Statement Chart

Total Revenue

Gross Profit

Cumberland Pharmaceuticals income statement Correlations

Cumberland Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Cumberland Pharmaceuticals income statement Accounts

Also Currently Popular

Additional Tools for Cumberland Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Operating Expenses	+ 0.99	Other Operating Expenses
Income Before Tax	+ 0.99	Operating Income
Gross Profit	+ 0.98	Total Revenue
Ebitda	+ 0.97	Ebit
Other Operating Expenses	+ 0.96	Selling General Administrative
Net Income	+ 0.96	Income Before Tax

Net Interest Income	- 0.82	Interest Expense
Reconciled Depreciation	- 0.81	Net Interest Income
Ebit	- 0.81	Depreciation And Amortization
Reconciled Depreciation	- 0.8	Discontinued Operations
Net Income	- 0.77	Depreciation And Amortization
Net Income From Continuing Ops	- 0.76	Cost Of Revenue